The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > ORGANIZATION
ORGANIZATION
- Economic Losses Due to Illness, Injury Total ¥3.3 Tril. Annually in Japan: ACCJ
November 28, 2011
- MSF Japan General Director Expresses Concern Over TPP Negotiations, Possible Generics Price Rise
November 25, 2011
- SAMURAI Biotech Association Presents Petition to Health Minister Calling for NHI Pricing System Reflecting Economic Assessment
November 25, 2011
- JPMA, FPMAJ Call on LDP Council on Budget and Tax System with Requests for Next Year
November 24, 2011
- JACDS Discusses Problems Expected from Ban on Dispensing Point Services
November 21, 2011
- Plaintiffs Appeal to the Supreme Court: Iressa Appeal Trial
November 18, 2011
- 6 Indian Generics Companies Including Zydus Form Association, to Start Operations This Month
November 18, 2011
- JPMA Postpones Announcement of Views on TPP,“Will Not Comment Based on Speculation”
November 17, 2011
- Plaintiffs Say High Court Ruling over Iressa “Completely Denies Goals in Medical Administration”
November 17, 2011
- Top JPWA Officials Stress Importance of Wholesalers in Urgent Press Conference
November 17, 2011
- NEDO Decides to Provide Assistance to Four Projects to Develop Bio-Pharmaceutical Manufacturing Technology
November 16, 2011
- JPMA Campaign Highlights Value of New Drug Development
November 15, 2011
- Foreign Countries Interested in Japan’s New Promotion of Generics: IGPA Annual Conference
November 14, 2011
- Premium for Development of New Drugs Is Fiscal Neutrality System: Mr Kamoya of JPMA
November 11, 2011
- JPWA's Bessho Says Promotion of Unit-Priced Contracts by Product First and Foremost
November 11, 2011
- Trial of Premium for New Drug Development Should Continue: Dr Suzuki of JMA
November 1, 2011
- Prescription Doubts Found in 3.15% of Prescriptions, 70% of Those Were Changed: JPA Survey
October 28, 2011
- FPMAJ to Request DPJ to Make Premiums Permanent
October 27, 2011
- JPA’s Yamamoto Calls for Deliberation on TPP after Clarification
October 25, 2011
- JMA Openly Opposes TPP; JPA, JDA, JNA Express Concern
October 24, 2011
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…